Cargando...

Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes

BACKGROUND: Based on a single placebo-controlled randomized clinical trial, empagliflozin is licensed to reduce cardiovascular death in diabetes and comorbid cardiovascular disease. METHODS: We examined the comparative effectiveness of empagliflozin on mortality and cardiovascular morbidity in type...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Transl Med
Main Authors: Aronow, Wilbert S., Shamliyan, Tatyana A.
Formato: Artigo
Idioma:Inglês
Publicado: AME Publishing Company 2017
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5733315/
https://ncbi.nlm.nih.gov/pubmed/29285488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2017.08.43
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!